The $10 million Abiomed (NSDQ:ABMD) put into Shockwave Medical (NSDQ:SWAV) has paid off so far no matter how you slice it. Shockwave raised nearly $97 million in an initial public offering earlier this month, inking a private-placement deal with Abiomed on the side for $10.0 million worth of SWAV shares at the $17-per-share IPO price. […]
Abiomed adds $10m to $97m Shockwave IPO
Shockwave Medical this week raised nearly $97 million from its initial public offering and inked a private-placement deal with Abiomed (NSDQ:ABMD) for another $10 million. Santa Clara, Calif.-based Shockwave, which is developing a device to treat calcified coronary lesions with sonic pressure waves, said March 6 that it floated 5.7 million shares at $17 apiece, […]
Shockwave Medical sets terms for $75m IPO
Shockwave Medical this week set terms for its initial public offering, looking to bring in approximately $75 million, according to an SEC filing. The Santa Clara, Calif.-based company said that it plans to float approximately 5 million shares of its common stock at a price between $14 and $16, according to the filing. The IPO will […]
Shockwave Medical registers for $70m IPO
Shockwave Medical has registered for an upcoming initial public offering worth $70 million, according to recently posted SEC filings. The Santa Clara, Calif.-based vascular tech developer is looking to list its common stock on the Nasdaq Global Market under the symbol “SWAV,” according to the filing. Net proceeds from the offering are slated to support […]
Shockwave Medical launches U.S. pivotal for coronary lithotripsy
Shockwave Medical said today that it launched a U.S. pivotal trial for its coronary lithotripsy device, which is designed to prepare heavily calcified coronary lesions for stenting. The technology uses sonic pressure waves to fracture intimal and medial calcium without damaging arterial tissue, Santa Clara, Calif.-based Shockwave said. Last April the Shockwave S4 catheter, designed to similarly treat […]
Abiomed puts $15m into Shockwave
Abiomed (NSDQ:ABMD) plans to invest $15 million in Shockwave Medical and collaborate on a training and education program in the U.S. and Germany, according to a newly-inked deal between the two companies. Shockwave’s intravascular lithotripsy technology uses sonic pressure waves to crack vascular calcium in the vessel wall, allowing arteries to expand under low pressure. The […]
Shockwave wins CE Mark for S4 peripheral lithotripsy catheter
Shockwave Medical said today it won CE Mark approval in the European Union for its Shockwave S4 peripheral intravascular lithotripsy catheter. The Shockwave S4 is a low-profile catheter designed to treat calcified lesions below-the-knee arteries, which can be challenging to access and treat, and are often associated with critical limb ischemia. The company’s Lithoplasty devices are designed […]
Shockwave Medical raises $35m for Lithoplasty devices
Shockwave Medical said today that it raised another $35 million for the Lithoplasty devices it’s commercializing to treat blocked arteries. Fremont, Calif.-based Shockwave said it plans to use the new funding, which was led by new backer Fidelity Management & Research, to commercialize its existing devices for treating coronary and peripheral vessels in the U.S. and Europe […]
Shockwave Medical touts Disrupt BTK lithoplasty system study results
Shockwave Medical today released results from the Disrupt below the knee study of its Shockwave Lithoplasty system designed to treat peripheral artery disease, touting low rates of residual stenosis and low vascular complications. Data from the study was presented at the annual Cardiovascular and Interventional Radiological Society of Europe congress in Copenhagen, Denmark. “Interventional procedures that […]
Shockwave wins CE Mark for coronary Lithoplasty device
Shockwave Medical said today that it won CE Mark approval in the European Union for its coronary Lithoplasty system. The therapy is designed to treat calcified coronary artery blockages with lithotripsy – sonic pressure waves that are traditionally used to treat patients with kidney stones. The approval was supported by clinical data from the Disrupt […]
Shockwave Medical picks up ex-HeartWare CEO Godshall | Personnel Moves – May 11, 2017
Shockwave Medical said today it tapped former HeartWare CEO Doug Godshall as its new prez & CEO. Godshall served as CEO of HeartWare for 10 years until the business was acquired by Medtronic (NYSE:MDT) for $1.1 billion last August, Fremont, Calif.-based Shockwave Medical said. Prior to his time at HeartWare, Godshall held various executive and leadership […]
MassDevice Network
@MassDevice
LinkedIn
YouTube